Institute of Plant Genetics Polish Academy of Sciences, Strzeszyńska 34, 60-479 Poznań, Poland.
Curr Pharm Biotechnol. 2012 Dec;13(15):2692-704. doi: 10.2174/138920112804724837.
Prevention of hepatitis B, one of the most prevalent human diseases, still requires cheap and commonly available vaccines. Oral vaccines, including plant-based formulations, have been considered as alternatives or supplements for standard injection vaccines, due to the assumed low-cost production and simplified vaccination. Although plant production of HBV antigens is sufficiently efficient, despite almost 20 years of research still no anti-HBV plant-based vaccine has been developed. The basic difficulty has been to elaborate an effective immunisation procedure. Immunisation by parenteral priming and oral boosting with raw plant tissue adjuvanted with the cholera toxin, although effective, seemed to be unfeasible and controversial. Exclusively oral immunisation using lyophilised tissue, despite its appropriate form, appeared also impractical because of too low efficiency. Oral tolerance turned out to be the main barrier for anti-HBV plant-based vaccines. Based on previous results and knowledge on the mucosal immune system, a possible vaccine may consist of two components, parenteral for priming and oral for boosting. Probably the oral constituent could independently serve for further booster vaccinations. Both vaccine components can be produced in plants and used after some processing - purification for the injection constituent and lyophilisation for the oral one. Lyophilised tissue can be converted into tablets, capsules, etc. Previous and recent data show that the injection-oral immunisation regime may be efficient. A combination of parenteral and oral vaccination offers good prospects for a truly efficacious plant-derived anti-HBs vaccine and even a partial substitution of parenteral vaccines by an oral formula may prove to be economically reasonable.
乙型肝炎是最常见的人类疾病之一,其预防仍然需要廉价且普遍可用的疫苗。口服疫苗,包括基于植物的制剂,已被认为是标准注射疫苗的替代品或补充剂,因为它们假设生产成本低且接种方式简化。尽管植物生产 HBV 抗原的效率已经足够高,但经过近 20 年的研究,仍然没有开发出基于植物的抗 HBV 疫苗。基本的困难在于制定有效的免疫程序。尽管通过肠道免疫原性和口服佐剂(用霍乱毒素增强)进行的免疫接种是有效的,但似乎不可行且存在争议。尽管冻干组织的口服免疫接种形式合适,但由于效率太低,也不太可行。口服耐受是基于植物的抗 HBV 疫苗的主要障碍。基于先前的结果和对黏膜免疫系统的了解,一种可能的疫苗可能由两部分组成,一部分用于肠道免疫原性,另一部分用于口服增强。可能口服成分可以独立用于进一步的增强免疫接种。两种疫苗成分都可以在植物中生产,并在经过一些处理后使用 - 注射成分需要纯化,口服成分需要冻干。冻干组织可以转化为片剂、胶囊等。先前和最近的数据表明,肠道免疫接种和口服免疫接种的组合可能是有效的。肠道免疫接种和口服免疫接种的结合为真正有效的基于植物的抗 HBs 疫苗提供了良好的前景,甚至通过口服配方部分替代肠道疫苗也可能在经济上是合理的。